dexketoprofen rompharm
lex ano, uab - deksketoprofenas - injekcinis ar infuzinis tirpalas - 50 mg/2 ml - dexketoprofen
imjudo
astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antinavikiniai vaistai - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
tremelimumab astrazeneca
astrazeneca ab - tremelimumab - karcinoma, nesmulkiųjų ląstelių skausmas - antinavikiniai vaistai - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
dexketoprofen rompharm
ideal trade links, uab - deksketoprofenas - injekcinis ar infuzinis tirpalas - 50 mg/2 ml - dexketoprofen
dexketoprofeno normon
lex ano, uab - deksketoprofenas - injekcinis ar infuzinis tirpalas - 50 mg/2 ml - dexketoprofen